EZH2 and neoplasm: Future studies will focus on understanding whether T-cell activation and subsequent IFNγ signaling are major drivers of increased MHCI and MHCII on tumor cells in vivo, and whether cells other than T cells, such as neutrophils, are required for tumor stasis in response to EZH2 inhibitor.